查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1912755

幼年特发性关节炎诊断市场（依产品类型、技术及最终用户划分）－2026-2032年全球预测

Juvenile Idiopathic Arthritis Diagnostic Market by Product Type, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年幼年特发性关节炎诊断市场价值为 2.3011 亿美元，预计到 2026 年将成长至 2.563 亿美元，预计到 2032 年将达到 4.7056 亿美元，复合年增长率为 10.75%。

关键市场统计数据
基准年 2025 2.3011亿美元
预计年份：2026年 2.563亿美元
预测年份 2032 4.7056亿美元
复合年增长率 (%) 10.75%

一个涵盖诊断挑战和跨学科必要性的综合框架，定义了现代检测和分诊幼年特发性关节炎的方法

由于临床表型多样、发炎标记重迭，以及需要及时介入以防止不可逆的关节损伤和发育影响，幼年特发性关节炎的诊断极具挑战性。早期准确区分少关节型、多关节型和系统性关节炎对于优化治疗方案、最大限度地减少糖皮质激素暴露以及根据患者独特的免疫病理特征制定生物製剂治疗方案至关重要。诊断流程越来越依赖综合方法，将详细的临床评估与有针对性的影像学检查和检测相结合，从而减少诊断延误和儿童诊疗指南的差异。

技术、临床和监管方面的变革正在共同推动幼年特发性关节炎的诊断朝着更早期、更个人化和更​​实证的方向发展。

由于技术、监管和临床趋势的融合，幼年特发性关节炎的诊断格局正在发生变革，这些趋势提高了诊断准确性和医疗服务的整合性。分子和生物标记主导的策略透过引入能够区分自体免疫特征、细胞激素谱和遗传易感性的检测组合，减少了对特异性发炎标记物的依赖。同时，影像技术也在不断发展。高解析度磁振造影（MRI）通讯协定的开发和肌肉骨骼超音波的广泛应用，使得在最大限度减少辐射暴露的同时，能够早期发现滑膜炎、腱鞘炎和侵蚀性变化。这些影像技术的进步与自动化判读工具和影像引导的诊断工作流程相辅相成，缩短了诊断时间，并提高了观察者间的一致性。

评估2025年美国关税政策对儿童关节炎诊断的诊断设备、试剂供应链和营运筹资策略的影响

2025年美国实施的关税调整和贸易措施对幼年特发性关节炎诊断所需的诊断设备、试剂和耗材的采购、生产和分销产生了显着影响。进口资本设备和特殊试剂关税的提高给检查室营运预算带来了压力，并可能影响MRI扫描仪、超音波探头和照护现场设备的采购决策。为此，医疗机构和诊断设备供应商已开始重新评估其供应商组合，优先选择具有本地生产或区域分销能力的供应商，以最大限度地减少进口成本波动的影响。

多维度细分洞察揭示了产品类型、技术、最终用户和检测方法如何相互关联，从而驱动诊断选择和临床整合。

详细的細項分析揭示了不同诊断方式和最终用户之间的交集，从而影响临床路径和商业性优先事项。按产品类型评估时，影像诊断和检查室诊断之间的区别至关重要。影像诊断包括磁振造影（MRI）、超音波和X光等方式，这些方式对于可视化滑膜发炎和结构变化至关重要。另一方面，检查室诊断包括生物标记检测、基因检测和血清学检测，这些检测用于检查免疫特征和疾病易感性。在生物标记检测中，诸如急性期蛋白检测、自体抗体检测和细胞激素检测等子类别在特异性和实际效用方面存在差异，这会影响基于临床症状和治疗目标的检测选择。

各地区特定的诊断部署模式和营运重点将影响美洲、欧洲、中东和非洲以及亚太地区的采用率和可近性。

区域趋势将对三大主要宏观区域的诊断实务模式、监管参与和供应链策略产生重大影响。在美洲，先进的三级医疗中心和社区医院优先考虑快速、可报销的诊断方式，这正在塑造临床应用，推动高分辨率成像和检验的生物标誌物检测的普及，同时要求提供明确的临床效用证据才能获得支付方的报销。对就地检验和远端医疗的过渡性投资正在扩大服务不足地区的医疗覆盖范围。同时，采购部门对成本压力和关税政策的敏感度正在影响供应商的选择和合约结构。

诊断创新者如何利用平台差异化、临床伙伴关係和整合式医疗解决方案来加速应用和临床检验

在幼年特发性关节炎诊断领域，各公司正透过平台创新、临床伙伴关係和精准的市场推广策略来实现差异化竞争。诊断设备製造商正在拓展服务模式和临床支持，以加速影像和照护现场设备的普及应用；而检测开发人员则优先考虑分析的稳健性、多重检测能力和临床检验，以证明其在儿童人群中的效用。诊断公司与学术机构之间的策略合作正在加速生物标记的发现，并将基于研究的检测方法转化为检验的临床检测方法。

儿童风湿病诊断开发人员和医疗保健领导者在提高检验、供应链弹性、完整性和医疗保健协作方面的实际策略重点

产业领导者应优先采取一系列切实可行的措施来改善诊断并巩固商业性地位。首先，投资进行多学科临床检验研究，将生物标记和影像学结果与治疗决策和长期疗效联繫起来，以证明其临床效用并为医保报销谈判提供支持。其次，透过供应商多元化、推进关键试剂的本地化生产以及建立紧急库存策略来增强供应链韧性，从而减少进口中断带来的影响。第三，与儿童风湿病中心和参考实验室建立策略伙伴关係，以加速产生真实世界证据，并改善各种临床环境下的检测流程。

我们采用透明的混合调查方法框架，结合专家访谈、临床文献综合和技术评估，来支持我们的诊断结果和建议。

为确保严谨性和相关性，本分析采用结构化的研究途径，结合与关键相关人员的直接对话和系统性的文献综述，对证据进行综合分析。关键资讯包括对儿童风湿症医师、检查室主任、放射科医生和供应链经理的深入访谈，以了解临床工作流程、检验要求和采购限制。这些定性研究结果与对同行评审的临床文献、监管申报文件和技术性能数据的有针对性审查进行三角验证，以检验分析假设并为临床效用论点提供背景资讯。

整合诊断机会和营运需求，将技术进步转化为儿童风湿病护理方面可衡量的改进。

总之，在影像技术、生物标记科学和分子诊断技术进步的推动下，幼年特发性关节炎的诊断路径正朝着更精准、整合和以患者为中心的方向发展。这些进步为缩短诊断延迟、对患者进行分层以进行标靶治疗以及改善长期功能预后创造了机会。然而，成功实施这些方法需要协调一致的临床验证、稳健的供应链策略以及与支付方的积极合作，以确保新的检验和平台能够在不同的医疗机构中得到应用。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的幼年特发性关节炎诊断市场

  • 影像诊断
    • MRI
    • 超音波
    • X射线
  • 检查室诊断
    • 生物标记检测
      • 急性期蛋白测定
      • 自体抗体检测
      • 细胞激素测量
    • 基因检测
    • 血清学检测

9. 按技术分類的幼年特发性关节炎诊断市场

  • ELISA
  • 流式细胞技术
  • PCR技术

第十章 依最终使用者分類的幼年特发性关节炎诊断市场

  • 诊断检查室
  • 医院
  • 研究所
  • 专科诊所

第十一章 各地区幼年特发性关节炎诊断市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 依组别分類的幼年特发性关节炎诊断市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国幼年特发性关节炎诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章美国青少年特发性关节炎诊断市场

第十五章 中国幼年特发性关节炎诊断市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • F. Hoffmann-La Roche AG
  • Mayo Clinic
  • Ortho Clinical Diagnostics Holdings plc
  • QIAGEN NV
  • Randox Laboratories Ltd
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-AE420CB13A79

The Juvenile Idiopathic Arthritis Diagnostic Market was valued at USD 230.11 million in 2025 and is projected to grow to USD 256.30 million in 2026, with a CAGR of 10.75%, reaching USD 470.56 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 230.11 million
Estimated Year [2026] USD 256.30 million
Forecast Year [2032] USD 470.56 million
CAGR (%) 10.75%

Comprehensive framing of diagnostic challenges and multidisciplinary imperatives that define contemporary approaches to juvenile idiopathic arthritis detection and triage

Juvenile idiopathic arthritis presents a complex diagnostic challenge driven by heterogeneous clinical phenotypes, overlapping inflammatory markers, and the need for timely intervention to prevent irreversible joint damage and developmental impacts. Early and accurate differentiation among oligoarticular, polyarticular, and systemic presentations remains central to optimizing therapeutic trajectories, minimizing corticosteroid exposure, and aligning biologic therapies with patient-specific immunopathology. Diagnostic pathways increasingly rely on integrated approaches that combine detailed clinical assessment with targeted imaging and laboratory assays to reduce diagnostic delay and guideline variations across pediatric care settings.

Advances in immunology, molecular genetics, and imaging technology have created opportunities to refine diagnostic criteria and to identify subgroups prone to aggressive disease or extra-articular complications. At the same time, clinical workflows must accommodate evolving assay availability, payer requirements, and specialist referral patterns. Consequently, multidisciplinary coordination between pediatric rheumatologists, radiologists, pathologists, and laboratory medicine teams is vital. This introductory framing sets the stage for deeper analysis of technological innovation, segmentation dynamics, regulatory influences, and operational priorities that shape diagnostic decision-making in contemporary pediatric rheumatology.

How converging technological, clinical, and regulatory shifts are reshaping juvenile idiopathic arthritis diagnostics toward earlier, more personalized, and evidence-driven care

The diagnostic landscape for juvenile idiopathic arthritis is undergoing transformative shifts propelled by converging technological, regulatory, and clinical trends that enhance diagnostic precision and care integration. Molecular and biomarker-driven strategies are reducing reliance on nonspecific inflammatory markers by introducing panels that differentiate autoimmune signatures, cytokine profiles, and genetic predispositions. Concurrently, imaging capabilities have evolved: higher-resolution MRI protocols and the expanded use of musculoskeletal ultrasound enable earlier detection of synovitis, tenosynovitis, and erosive changes while minimizing radiation exposure. These imaging improvements are complemented by automated reading tools and image-guided diagnostic workflows that shorten time to diagnosis and improve inter-rater reliability.

On the technology side, assay platforms such as enzyme-linked immunosorbent assays, flow cytometry, and polymerase chain reaction-based methods permit multiplexed and quantitative analyses that support stratified therapeutic choices. The proliferation of point-of-care platforms and rapid serological assays is altering outpatient decision pathways while digital health and artificial intelligence tools are beginning to assist in pattern recognition and risk stratification. Regulatory emphasis on clinical validity and utility, along with evolving reimbursement frameworks that reward diagnostic value, is reshaping product development strategies. Taken together, these shifts are fostering a more nuanced, evidence-driven approach to diagnosis that emphasizes earlier intervention and personalized management plans.

Assessment of 2025 US tariff policy impacts on diagnostic equipment, reagent supply chains, and operational procurement strategies affecting pediatric arthritis diagnostics

Tariff changes and trade measures implemented in the United States in 2025 have introduced notable implications for the procurement, production, and distribution of diagnostic equipment, reagents, and consumables that underpin juvenile idiopathic arthritis diagnostics. Increased duties on imported capital equipment and specialty reagents create pressure on laboratory operating budgets and can alter purchasing decisions for MRI scanners, ultrasound probes, and point-of-care devices. In response, healthcare providers and diagnostic vendors have begun reassessing supplier portfolios, prioritizing vendors with localized manufacturing or regional distribution capabilities to minimize exposure to import-related cost volatility.

Supply chain resilience has become a defining operational priority, prompting longer-term contracts with multiple suppliers, increased inventory buffers for critical reagents, and selective onshoring of manufacturing for high-value components. These adjustments have secondary effects on clinical adoption timetables, as procurement cycles extend and capital planning becomes more conservative. In parallel, some stakeholders are accelerating collaborations with domestic manufacturers and contract development organizations to safeguard continuity of novel assays and specialized consumables. Collectively, these dynamics signal a strategic pivot toward supply diversification and contractual flexibility that aims to preserve diagnostic quality while containing cost pressures arising from tariff policy changes.

Multidimensional segmentation insights revealing how product categories, technologies, end users, and test modalities interrelate to drive diagnostic selection and clinical integration

A granular view of segmentation illuminates how different diagnostic modalities and end users intersect to shape clinical pathways and commercial priorities. When evaluating by product type, distinctions between imaging diagnostics and laboratory diagnostics matter greatly; imaging diagnostics encompass MRI, ultrasound, and X-ray modalities that are critical for visualizing synovial inflammation and structural change, whereas laboratory diagnostics include biomarker tests, genetic tests, and serological tests that interrogate immune signatures and disease predisposition. Within biomarker tests, subcategories such as acute phase protein assays, autoantibody assays, and cytokine assays offer varying degrees of specificity and real-world clinical utility, influencing test selection based on clinical presentation and therapeutic intent.

Technology segmentation further clarifies performance trade-offs and workflow integration. Enzyme-linked immunosorbent assays remain a backbone for quantitative biomarker assessment, flow cytometry enables cellular phenotyping and immunophenotyping, and PCR-based technologies provide sensitive detection of genetic variants and pathogen-associated molecular signatures. End-user segmentation delineates operational contexts: diagnostic laboratories, hospitals, research laboratories, and specialty clinics each have distinct throughput, validation requirements, and integration capabilities that affect which platforms and assays are practical for routine use. Test-type considerations parse invasive approaches, including arthrocentesis and synovial biopsy, from noninvasive options such as blood tests and imaging procedures. Blood-based testing often leverages biomarker, genetic, and serological analyses, while imaging procedures emphasize MRI and ultrasound modalities. Understanding these layered segmentations is essential for aligning diagnostic development with clinical adoption pathways and laboratory capacities.

Region-specific diagnostic adoption patterns and operational priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence deployment and access

Regional dynamics significantly influence diagnostic practice patterns, regulatory interactions, and supply chain strategies across the three principal macro-regions. In the Americas, clinical adoption is shaped by a mix of advanced tertiary care centers and community hospitals that prioritize rapid, reimbursable diagnostics; this environment supports adoption of high-resolution imaging and validated biomarker assays, but also demands clear evidence of clinical utility to secure payer reimbursement. Transitional investments in point-of-care testing and telehealth are expanding access in underserved areas, while procurement sensitivity to cost pressures and tariff policy influences vendor selection and contract structuring.

In Europe, Middle East & Africa, heterogeneity in healthcare infrastructure, regulatory frameworks, and reimbursement pathways leads to varied adoption rates for advanced diagnostics. High-capacity centers in western Europe frequently integrate molecular and imaging platforms into pediatric rheumatology care, whereas resource-constrained settings in other parts of the region often prioritize scalable, cost-effective laboratory assays and portable imaging solutions. Collaborative networks and clinician training programs are important mechanisms for elevating diagnostic standards across the region. Asia-Pacific exhibits rapid technology adoption driven by a large patient base, strong private sector investment, and active public health modernization efforts. Here, diverse regulatory landscapes and manufacturing capabilities create opportunities for local production of assays and devices, which can improve access and reduce dependency on long international supply chains. These regional nuances underscore the need for tailored market entry and deployment strategies that align clinical, regulatory, and operational realities.

How diagnostic innovators are leveraging platform differentiation, clinical partnerships, and integrated care solutions to accelerate adoption and clinical validation

Companies operating in the juvenile idiopathic arthritis diagnostic space are differentiating through a combination of platform innovation, clinical partnerships, and targeted go-to-market strategies. Diagnostic equipment manufacturers are extending service models and clinical support to accelerate adoption of imaging and point-of-care devices, while assay developers are emphasizing analytical robustness, multiplexing capability, and clinical validation to demonstrate utility in pediatric populations. Strategic collaborations between diagnostic firms and academic centers are accelerating biomarker discovery and the translation of research assays into validated clinical tests.

Commercial leaders are also developing modular solutions that integrate laboratory information systems, imaging outputs, and clinical decision support to create more seamless diagnostic workflows. Investment in regulatory strategy and payer engagement is becoming a competitive advantage, as firms that can demonstrate clinical pathways and cost-effectiveness gain preferential uptake in hospital systems and specialty clinics. In addition, contract research organizations and specialty laboratories are forming strategic alliances to support assay development, clinical validation, and post-market surveillance, enabling faster scale-up of novel tests while maintaining quality and compliance.

Actionable strategic priorities for diagnostic developers and healthcare leaders to enhance validation, supply resilience, integration, and payer alignment in pediatric rheumatology

Industry leaders should prioritize a set of practical actions to realize diagnostic improvements and to strengthen commercial positioning. First, invest in cross-disciplinary clinical validation studies that link biomarker and imaging readouts to treatment decisions and long-term outcomes, thereby demonstrating clinical utility and supporting reimbursement discussions. Second, build supply chain resilience by diversifying suppliers, pursuing localized manufacturing for critical reagents, and establishing contingency inventory strategies to mitigate import-related disruptions. Third, pursue strategic partnerships with pediatric rheumatology centers and reference laboratories to accelerate real-world evidence generation and to refine testing algorithms for different clinical settings.

Leaders should also focus on product interoperability and data integration, ensuring that assay outputs and imaging reports feed into electronic health records and decision support tools to streamline clinician workflows. Targeted education programs for primary care providers and referral networks will reduce diagnostic delay and increase appropriate test utilization. Finally, adopt adaptive pricing and contracting models that reflect the value delivered in specific care settings, while maintaining transparent dialogue with payers to align reimbursement pathways with demonstrated clinical benefits. Implementing these measures will enhance adoption, patient outcomes, and operational sustainability in diagnostic portfolios.

Transparent, mixed-methods research framework combining expert interviews, clinical literature synthesis, and technology assessments to underpin diagnostic insights and recommendations

This analysis synthesizes evidence from a structured research approach that combines primary stakeholder engagement with systematic secondary review to ensure rigor and relevance. Primary inputs included in-depth interviews with pediatric rheumatologists, laboratory directors, radiologists, and supply chain managers to capture clinical workflows, validation expectations, and procurement constraints. These qualitative insights were triangulated with a targeted review of peer-reviewed clinical literature, regulatory filings, and technology performance data to verify analytical assumptions and to contextualize clinical utility claims.

Technology assessments incorporated analytical performance metrics, sample throughput characteristics, and compatibility with routine laboratory infrastructure. Regulatory and reimbursement landscapes were examined through public guidance documents and payer policy statements to identify adoption barriers and enablers. Wherever possible, clinical validity findings were cross-checked against independent validation studies and consensus guidelines to ensure that recommendations reflect broadly accepted standards. The research process emphasized transparent documentation of sources, methodological limitations, and areas where further clinical evidence would materially improve diagnostic certainty.

Synthesis of diagnostic opportunities and operational imperatives that convert technological advances into measurable improvements in pediatric rheumatology care

In conclusion, diagnostic pathways for juvenile idiopathic arthritis are transitioning toward more precise, integrated, and patient-centered approaches driven by advances in imaging, biomarker science, and molecular diagnostics. These developments create opportunities to reduce diagnostic delay, to stratify patients for targeted therapies, and to improve long-term functional outcomes. However, successful implementation depends on coordinated clinical validation, robust supply chain strategies, and constructive payer engagement to ensure that new assays and platforms are adoptable across diverse care settings.

Operational resilience, data integration, and clinician education are essential complements to technological innovation; together, they convert diagnostic potential into measurable improvements in care. By aligning research, commercialization, and clinical adoption strategies, stakeholders can accelerate the translation of promising diagnostics into routine practice, ultimately improving detection, treatment selection, and monitoring for children affected by juvenile idiopathic arthritis.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Juvenile Idiopathic Arthritis Diagnostic Market, by Product Type

  • 8.1. Imaging Diagnostics
    • 8.1.1. MRI
    • 8.1.2. Ultrasound
    • 8.1.3. X Ray
  • 8.2. Laboratory Diagnostics
    • 8.2.1. Biomarker Tests
      • 8.2.1.1. Acute Phase Protein Assays
      • 8.2.1.2. Autoantibody Assays
      • 8.2.1.3. Cytokine Assays
    • 8.2.2. Genetic Tests
    • 8.2.3. Serological Tests

9. Juvenile Idiopathic Arthritis Diagnostic Market, by Technology

  • 9.1. ELISA
  • 9.2. Flow Cytometry
  • 9.3. PCR Technology

10. Juvenile Idiopathic Arthritis Diagnostic Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
  • 10.3. Research Laboratories
  • 10.4. Specialty Clinics

11. Juvenile Idiopathic Arthritis Diagnostic Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Juvenile Idiopathic Arthritis Diagnostic Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Juvenile Idiopathic Arthritis Diagnostic Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Juvenile Idiopathic Arthritis Diagnostic Market

15. China Juvenile Idiopathic Arthritis Diagnostic Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Bio-Rad Laboratories, Inc.
  • 16.7. bioMerieux SA
  • 16.8. F. Hoffmann-La Roche AG
  • 16.9. Mayo Clinic
  • 16.10. Ortho Clinical Diagnostics Holdings plc
  • 16.11. QIAGEN N.V.
  • 16.12. Randox Laboratories Ltd
  • 16.13. Siemens Healthineers AG
  • 16.14. Sysmex Corporation
  • 16.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ACUTE PHASE PROTEIN ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ACUTE PHASE PROTEIN ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ACUTE PHASE PROTEIN ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY AUTOANTIBODY ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY AUTOANTIBODY ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY AUTOANTIBODY ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY CYTOKINE ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY CYTOKINE ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY CYTOKINE ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY GENETIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY GENETIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SEROLOGICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SEROLOGICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SEROLOGICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PCR TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PCR TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PCR TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 130. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 131. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 132. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 151. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 152. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 153. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. G7 JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 158. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 160. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY IMAGING DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY LABORATORY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY BIOMARKER TESTS, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)